|

Sofetabart Mipitecan Clinical Trials

1 actively recruiting trial across 1 location

Also known as: LY4170156

Pipeline

Phase 3: 1

Top Sponsors

  • Eli Lilly and Company1

Indications

  • Peritoneal Neoplasms1
  • Fallopian Tube Neoplasms1
  • Ovarian Neoplasms1
  • Neoplasm Metastasis1
  • Cancer1

Birmingham, Alabama1 trial

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.